title: Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation.
abstract: Antibodies to heparin platelet factor 4 (H-PF4) complexes were purified from the plasma of three patients with heparin-induced thrombocytopenia (HIT) using affinity chromatography. From each plasma, the largest amount of antibodies was eluted with 2 M NaCl at pH 7.5 (peak 1) and the remainder was obtained using 0.1 M glycine/0. 5 M NaCl at pH 2.5 (peak 2). In an enzyme-linked immunosorbent assay (ELISA), we then showed that each patient had developed antibodies to PF4 displaying different characteristics. In patient 1, peak 1 IgG reacted almost exclusively with H-PF4 complexes, whereas peak 2 IgG had similar reactivity with PF4 whether or not heparin was present. Patient 2 expressed a mixture of IgA, IgM and IgG and both fractions bound to PF4 alone or to H-PF4 complexes. Finally, IgG in patient 3 only bound to H-PF4 and was unreactive with PF4 alone. Using [14C]-serotonin release assays, the antibodies developed in the three patients and exhibiting the strongest ability to activate platelets with heparin were those having the highest affinity to H-PF4. These results strongly support the hypothesis that HIT antibodies to PF4 are heterogeneous regarding their affinity and specificity for target antigens and this may greatly influence their ability to activate platelets and their pathogenicity.
authors.affiliation: HYPHEN BioMed, 8 avenue Fin d'Oise, 78570 Andrésy, France.
authors.forename: J
authors.initials: J
authors.lastname: Amiral
authors.forename: C
authors.initials: C
authors.lastname: Pouplard
authors.forename: A M
authors.initials: AM
authors.lastname: Vissac
authors.forename: J M
authors.initials: JM
authors.lastname: Walenga
authors.forename: W
authors.initials: W
authors.lastname: Jeske
authors.forename: Y
authors.initials: Y
authors.lastname: Gruel
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects* / Q000276:immunology; D000937:Antigen-Antibody Reactions; D001323:Autoantibodies / Q000302:isolation & purification* / Q000494:pharmacology; D002846:Chromatography, Affinity; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D015539:Platelet Activation / Q000187:drug effects; D010978:Platelet Factor 4 / Q000276:immunology*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology
chemical_list: D000925:Anticoagulants; D001323:Autoantibodies; D010978:Platelet Factor 4; D006493:Heparin